CannaPharmaRx to Hold Investor Conference Call

CALGARY, AB / ACCESSWIRE / March 7, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it will hold an investor conference call on Tuesday, March19, 2024 at 2PM Eastern time to give an update on the year to date progress of CannaPharmaRx Inc.

Chief Executive Officer Dean Medwid will be presenting with the topics being discussed will include:

• Review of 2023 Operational Activities
• Licensing Update
• Product Update
• Supply Partner(s) Update
• Forecasted Revenues

Interested parties can join the conference call by dialing in as directed below.

	North American Toll Free: 1-530-881-1212	Passcode:	1674609
	PIN: 615253385#	Passcode:	1674609

An archived replay of the webcast will be available at: https://investors.trulieve.com/events

Please visit www.cannapharmarx.com for additional information about our company and products

About CannapharmaRx, Inc.
CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.

Safe Harbor Statement

Cautionary Note Regarding Forward-Looking Information or Statements
This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are 'forward-looking information or statements.' Forward-looking information or statements can be identified by the use of words such as 'plans,' 'expects,' or 'does not expect,' 'is expected,' 'estimates,' 'intends,' 'anticipates,' or 'does not anticipate,' or 'believes,' or variations of such words and phrases or statements that certain actions, events or results 'may,' 'could,' 'would,' 'might' or 'will' be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

Contact Information:
Brokers and Analysts
Chesapeake Group
[phone]

SOURCE: Cannapharmarx, Inc.

View the original press release on accesswire.com


The Cannapharmarx Stock at the time of publication of the news with a raise of +20,00 % to 0,018USD on Nasdaq OTC stock exchange (07. März 2024, 02:10 Uhr).